828P - Bone Metastases from Rcc are not Always Associated with a Poor Prognosis

Abstract

ABSTRACT Aim: Bone represents an unfavorable site of metastasis for renal cell carcinoma (mRCC), being associated with poorer prognosis compared to other metastatic sites. Aim of this study was to investigate for the presence of existing prognostic factors in patients with bone metastases from RCC. Methods: Data of patients with bone metastases from RCC were retrospectively collected from 16 Italian centers. Survival estimates were quantified using Kaplan Meier curves. Age, sex, ECOG-Performance Status (PS), MSKCC group, tumor histology, presence of visceral metastases, time from nephrectomy to bone metastasis (classified into three groups: 5 years) and time from bone metastasis to skeletal-related event (SRE) were included in the Cox analysis to investigate their prognostic relevance. Results: 470 patients were enrolled in this analysis; 235 of them were male. Median age was 64y (30-92y). In 19 patients (4%), bone was the only metastatic site; 277 patients (59%) had concomitant lung, 188 (40%) lymph nodes, 83 (18%) liver, 32 (7%) brain, and 12 (3%) adrenal metastases. Median time to bone metastasis was 16 months (range 0–44y). Median OS from bone disease was 17 months (95%CI:15-19 months). Number of metastatic sites (p = 0.01), concomitant metastases to liver (p = 0.006) and lymph-nodes (p = 0.02), high Fuhrman grade (p 5y) bone metastases had longer OS (22 months, 95%CI: 20-33) compared to patients with bone disease occurred Conclusions: The prognosis of RCC patients with bone metastases varies according to RCC histology, time of occurrence of bone metastases, presence of concomitant sites, MSKCC group and ECOG-PS. Disclosure: All authors have declared no conflicts of interest.